Profile data is unavailable for this security.
About the company
IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.
- Revenue in USD (TTM)1.35m
- Net income in USD-13.00m
- Incorporated2005
- Employees67.00
- LocationIGC Pharma Inc2405 York Road, Suite 201LUTHERVILLE-TIMONIUM 21093-2264United StatesUSA
- Phone+1 (301) 983-0998
- Fax+1 (240) 465-0273
- Websitehttps://igcpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ImmuCell Corp | 21.28m | -3.90m | 32.42m | 74.00 | -- | 1.31 | -- | 1.52 | -0.5030 | -0.5030 | 2.75 | 3.18 | 0.494 | 2.29 | 9.03 | 269,401.50 | -9.05 | -5.16 | -9.97 | -5.53 | 27.55 | 40.04 | -18.31 | -12.64 | 1.00 | -8.14 | 0.3204 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Quince Therapeutics Inc | 0.00 | -30.28m | 32.85m | 32.00 | -- | 0.4429 | -- | -- | -0.7599 | -0.7599 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -23.97 | -42.72 | -25.27 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1542 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| LianBio - ADR | 0.00 | -87.98m | 33.60m | 163.00 | -- | 0.1647 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -37.82m | 34.10m | 14.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | 0.5779 | 0.00 | -- | -- | 0.00 | -92.81 | -218.20 | -221.58 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Lipocine Inc | 4.71m | -8.97m | 34.28m | 17.00 | -- | 1.42 | -- | 7.28 | -1.71 | -1.71 | 0.8889 | 4.51 | 0.1585 | -- | 67.70 | 277,138.80 | -30.16 | -39.32 | -32.00 | -45.87 | -- | -- | -190.35 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Immuneering Corp | 0.00 | -54.18m | 35.29m | 65.00 | -- | 0.4483 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 35.35m | 8.00 | -- | 2.09 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Mink Therapeutics Inc | 0.00 | -20.59m | 35.65m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| IGC Pharma Inc | 1.35m | -13.00m | 35.88m | 67.00 | -- | 4.32 | -- | 26.68 | -0.2168 | -0.2168 | 0.0229 | 0.1098 | 0.0993 | 0.292 | 18.42 | 20,074.63 | -96.01 | -42.46 | -113.83 | -46.07 | 54.50 | 20.95 | -966.54 | -730.00 | 0.9252 | -- | 0.0188 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
| Cue Biopharma Inc | 7.02m | -49.97m | 36.12m | 53.00 | -- | 1.20 | -- | 5.14 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.05m | 36.28m | 4.00 | -- | 6.02 | -- | -- | -1.17 | -1.17 | 0.00 | 0.3807 | 0.00 | -- | -- | 0.00 | -194.65 | -- | -283.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Curis Inc | 9.81m | -47.73m | 37.25m | 48.00 | -- | 3.94 | -- | 3.80 | -8.68 | -8.68 | 1.77 | 1.61 | 0.1253 | -- | 4.39 | 204,416.70 | -60.97 | -37.25 | -69.58 | -41.12 | 97.60 | 96.05 | -486.45 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Xilio Therapeutics Inc | 0.00 | -70.96m | 37.28m | 73.00 | -- | 1.35 | -- | -- | -2.57 | -2.57 | 0.00 | 0.7474 | 0.00 | -- | -- | 0.00 | -73.11 | -- | -96.98 | -- | -- | -- | -- | -- | -- | -144.29 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Mira Pharmaceuticals Inc | 0.00 | -12.36m | 37.84m | 3.00 | -- | 11.99 | -- | -- | -0.8276 | -0.8276 | 0.00 | 0.2136 | 0.00 | -- | -- | 0.00 | -587.64 | -- | -1,721.90 | -- | -- | -- | -- | -- | -- | -2.63 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
| IN8BIO, Inc. | 0.00 | -31.04m | 38.04m | 31.00 | -- | 2.13 | -- | -- | -0.9154 | -0.9154 | 0.00 | 0.4049 | 0.00 | -- | -- | 0.00 | -123.61 | -74.18 | -145.63 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0556 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
Data as of Jul 23 2024. Currency figures normalised to IGC Pharma Inc's reporting currency: US Dollar USD
2.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 715.44k | 0.95% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 630.22k | 0.83% |
| Geode Capital Management LLCas of 31 Mar 2024 | 324.30k | 0.43% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 141.30k | 0.19% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 119.71k | 0.16% |
| Dearborn Partners LLCas of 31 Mar 2024 | 116.71k | 0.15% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 71.36k | 0.09% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 65.50k | 0.09% |
| Group One Trading LPas of 31 Mar 2024 | 37.31k | 0.05% |
| Truist Bank (Private Banking)as of 31 Mar 2024 | 36.67k | 0.05% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
